↓ Skip to main content

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, September 2024
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Readers on

mendeley
228 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 169 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 228 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 228 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Unspecified 16 7%
Other 16 7%
Researcher 15 7%
Student > Ph. D. Student 12 5%
Student > Postgraduate 12 5%
Other 30 13%
Unknown 127 56%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 64 28%
Unspecified 16 7%
Biochemistry, Genetics and Molecular Biology 5 2%
Arts and Humanities 3 1%
Agricultural and Biological Sciences 3 1%
Other 9 4%
Unknown 128 56%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 360. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2026.
All research outputs
#113,010
of 34,492,055 outputs
Outputs from New England Journal of Medicine
#2,787
of 38,491 outputs
Outputs of similar age
#1,441
of 338,546 outputs
Outputs of similar age from New England Journal of Medicine
#23
of 252 outputs
Altmetric has tracked 34,492,055 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 38,491 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 120.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,546 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 252 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.